Literature DB >> 20848323

Establishing targets for hypertension control in patients with comorbidities.

Carlos Feldstein1, Stevo Julius.   

Abstract

Most current guidelines recommend tighter blood pressure (BP) control in hypertensive patients with comorbidities. These recommendations are based on epidemiologic data indicating that cardiovascular risk increases at lower BP levels in hypertensive patients with comorbidities than in those without comorbidities. Hypertension guidelines usually reflect outcomes from previous studies, but current recommendations for patients with comorbidities have preceded the evidence. We review recent studies investigating whether these new targets can be achieved, whether they are well tolerated, and whether they positively affect the outcomes. The results of the few current studies about outcomes in lower BP target groups are either negative or somewhat--but not decidedly--positive. There is a need for new trials designed to evaluate the validity of current recommendations for tighter BP control in hypertensive patients with comorbidities. Additionally, existing data from published trials could be reanalyzed to provide further clarification.

Entities:  

Mesh:

Year:  2010        PMID: 20848323     DOI: 10.1007/s11906-010-0153-z

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  43 in total

1.  Hypertension in adults across the age spectrum: current outcomes and control in the community.

Authors:  Donald M Lloyd-Jones; Jane C Evans; Daniel Levy
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

2.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

3.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong
Journal:  Circulation       Date:  2008-12-15       Impact factor: 29.690

Review 4.  Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure.

Authors:  Joseph L Izzo; Alan H Gradman
Journal:  Med Clin North Am       Date:  2004-09       Impact factor: 5.456

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

6.  Lowering blood pressure reduces renal events in type 2 diabetes.

Authors:  Bastiaan E de Galan; Vlado Perkovic; Toshiharu Ninomiya; Avinesh Pillai; Anushka Patel; Alan Cass; Bruce Neal; Neil Poulter; Stephen Harrap; Carl-Erik Mogensen; Mark Cooper; Michel Marre; Bryan Williams; Pavel Hamet; Giuseppe Mancia; Mark Woodward; Paul Glasziou; Diederick E Grobbee; Stephen MacMahon; John Chalmers
Journal:  J Am Soc Nephrol       Date:  2009-02-18       Impact factor: 10.121

7.  Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial.

Authors:  Matthew R Weir; Fawn Yeh; Angela Silverman; Richard B Devereux; James M Galloway; Jeffrey A Henderson; William J Howard; Marie Russell; Charlton Wilson; Robert Ratner; John Sorkin; Jason G Umans; Jerome L Fleg; Mario Stylianou; Elisa Lee; Barbara V Howard
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-10       Impact factor: 3.738

8.  Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial.

Authors:  Paolo Verdecchia; Jan A Staessen; Fabio Angeli; Giovanni de Simone; Augusto Achilli; Antonello Ganau; Gianfrancesco Mureddu; Sergio Pede; Aldo P Maggioni; Donata Lucci; Gianpaolo Reboldi
Journal:  Lancet       Date:  2009-08-15       Impact factor: 79.321

9.  Telmisartan to prevent recurrent stroke and cardiovascular events.

Authors:  Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

10.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

View more
  1 in total

1.  Blood Pressure and Living Kidney Donors: A Clinical Perspective.

Authors:  Anjay Rastogi; Stanley Yuan; Farid Arman; Lewis Simon; Kelly Shaffer; Mohammad Kamgar; Niloofar Nobakht; Jonathan S Bromberg; Matthew R Weir
Journal:  Transplant Direct       Date:  2019-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.